CYCURIA

Live / Registered — Registered (as of 10 Mar 2026)

What this means for you

Registered since 10 Mar 2026. The owner can stop confusingly similar uses in the classes it covers.

Record

Serial number
79413314
Registration number
8163961
Mark type
Stylized text
Filed
12 Nov 2024
Published for opposition
20 Jan 2026
Registered
10 Mar 2026
Attorney of record
Alisa C. Simmons

Goods and services

  • Class 005 — Pharmaceuticals: Pharmaceutical preparations and formulations, and medicated health preparations, for use in the treatment or prevention of human and animal diseases, disorders and conditions, especially circulatory, respiratory, endocrine, neurologic, cardiovascular, alimentary, pulmonary, musculoskeletal, lymphatic and gastrointestinal diseases, disorders and conditions, and the treatment or prevention of complications associated with such diseases, disorders and conditions; pharmaceutical preparations and formulations, and medicated health preparations, for use in the treatment or prevention of human and animal diseases, disorders and conditions, especially bone sensory, viral, urinary, renal, metabolic and central nervous system diseases, disorders and conditions, and the treatment or prevention of complications associated with such diseases, disorders and conditions; pharmaceutical preparations and formulations, and medicated health preparations, for use in the treatment or prevention of human and animal diseases, disorders and conditions, especially infectious, auto-immune and immune-related, cell-proliferative and oncologic diseases, disorders and conditions, cancers, tumours and metastases, and the treatment or prevention of complications associated with such diseases, disorders and conditions; diagnostic preparations and biomarker reagents for medical or veterinary purposes; diagnostic preparations and biomarker reagents for the diagnosis and prognosis of human and animal diseases, disorders and conditions, especially circulatory, respiratory, endocrine, neurologic, cardiovascular, alimentary, pulmonary, musculoskeletal, lymphatic and gastrointestinal diseases, disorders and conditions, and the diagnosis and prognosis of complications associated with such diseases, disorders and conditions; diagnostic preparations and biomarker reagents for the diagnosis and prognosis of human and animal diseases, disorders and conditions, especially bone sensory, viral, urinary, renal, metabolic and central nervous system diseases, disorders and conditions, and the diagnosis and prognosis of complications associated with such diseases, disorders and conditions; diagnostic preparations and biomarker reagents for the diagnosis and prognosis of human and animal diseases, disorders and conditions, especially infectious, auto-immune and immune-related, cell-proliferative and oncologic diseases, disorders and conditions, cancers, tumours and metastases, and the diagnosis and prognosis of complications associated with such diseases, disorders and conditions.
  • Class 042 — Scientific and technological services: Scientific services and research relating thereto, namely, scientific research; Scientific services and research relating thereto, namely, scientific research and development; Scientific services and research relating thereto, namely, scientific research for medical purposes in the field of cancerous diseases; Scientific services and research relating thereto, namely, scientific research, analysis, and testing in the fields of genomics, genetics, genetic engineering, biotechnology, and medicine; Scientific services and research relating thereto, namely, providing scientific research information in the field of genetics; Scientific services and research relating thereto, namely, providing scientific research information in the field of pharmaceuticals; Scientific services and research relating thereto, namely, scientific laboratory services; Scientific services and research relating thereto, namely, scientific research and scientific research information in the field of pharmaceuticals and clinical trials and conducting clinical trials for others; scientific services and research relating thereto, namely, scientific research, scientific research and development, analysis, and testing, and providing of scientific research information in the fields of biology, chemistry or medicine, as well as in the fields of immunology, oncology, molecular biology, cellular biology, biochemistry and medicinal chemistry as well as in the fields of discovery and development of pharmaceuticals, medical and veterinary preparations, diagnostic preparations and biomarker reagents and diagnostic apparatus; scientific services and research thereto, namely, scientific research, scientific research and development, analysis, and testing, and providing of scientific research information in the field of discovery of drug targets and drug candidates for the treatment or diagnostics of diseases, disorders and conditions in humans and animals, in particular in the fields of oncology, inflammatory-, autoimmune- and metabolic diseases; providing technical and scientific information about a biotechnology company, its technologies, projects, product-candidates, products and services via a web site on a global computer network; design and development of computer software; design and development of computer software for use in the fields of biology, chemistry or medicine, especially immunology, oncology, molecular biology, cellular biology, biochemistry and/or medicinal chemistry, as well as in the fields of discovery and development of pharmaceuticals, medical and veterinary preparations, diagnostic preparations and biomarker reagents and diagnostic apparatus.

Owner

Prosecution history

  • 10 Mar 2026 — NOTICE OF REGISTRATION CONFIRMATION EMAILED
  • 10 Mar 2026 — REGISTERED-PRINCIPAL REGISTER
  • 20 Jan 2026 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
  • 20 Jan 2026 — PUBLISHED FOR OPPOSITION
  • 14 Jan 2026 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
  • 20 Dec 2025 — APPROVED FOR PUB - PRINCIPAL REGISTER
  • 19 Dec 2025 — TEAS/EMAIL CORRESPONDENCE ENTERED
  • 19 Dec 2025 — CORRESPONDENCE RECEIVED IN LAW OFFICE
  • 19 Dec 2025 — TEAS RESPONSE TO OFFICE ACTION RECEIVED
  • 28 Aug 2025 — CHANGE OF NAME/ADDRESS REC'D FROM IB
  • 12 Aug 2025 — CORRECTION FROM IB ENTERED - NO REVIEW REQUIRED
  • 12 Jul 2025 — REFUSAL PROCESSED BY IB
  • 22 Jun 2025 — NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
  • 22 Jun 2025 — REFUSAL PROCESSED BY MPU
  • 24 Apr 2025 — NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW

View this trademark record on Marksy